News
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
Two Big Law firms guided Merck & Co.'s plans to purchase respiratory drugmaker Verona Pharma Plc for around $10 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback